GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soligenix Inc (NAS:SNGX) » Definitions » Interest Coverage

Soligenix (Soligenix) Interest Coverage : N/A (As of Dec. 2023)


View and export this data going back to 1994. Start your Free Trial

What is Soligenix Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Soligenix's Operating Income for the three months ended in Dec. 2023 was $-2.13 Mil. Soligenix's Interest Expense for the three months ended in Dec. 2023 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Soligenix's Interest Coverage or its related term are showing as below:


SNGX's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 127.155
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Soligenix Interest Coverage Historical Data

The historical data trend for Soligenix's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Soligenix Interest Coverage Chart

Soligenix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A - - - -

Soligenix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - N/A N/A

Competitive Comparison of Soligenix's Interest Coverage

For the Biotechnology subindustry, Soligenix's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Soligenix's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Soligenix's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Soligenix's Interest Coverage falls into.



Soligenix Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Soligenix's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Soligenix's Interest Expense was $-0.05 Mil. Its Operating Income was $-7.67 Mil. And its Long-Term Debt & Capital Lease Obligation was $1.12 Mil.

Soligenix did not have earnings to cover the interest expense.

Soligenix's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Soligenix's Interest Expense was $0.00 Mil. Its Operating Income was $-2.13 Mil. And its Long-Term Debt & Capital Lease Obligation was $1.12 Mil.

GuruFocus does not calculate Soligenix's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Soligenix  (NAS:SNGX) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Soligenix Interest Coverage Related Terms

Thank you for viewing the detailed overview of Soligenix's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Soligenix (Soligenix) Business Description

Traded in Other Exchanges
N/A
Address
29 Emmons Drive, Suite B-10, Princeton, NJ, USA, 08540
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
Executives
Timothy R. Cote director 3529 TILDEN STREET, NW, WASHINGTON DC 20008
Richard Straube officer: CMO 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Christopher Schaber director, officer: Chairman, CEO and President 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Jonathan L. Guarino officer: Chief Financial Officer 100 WELLESLEY WAY, FREEHOLD NJ 07728
Oreola Donini officer: CSO 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Robert J. Rubin director 7901 SPRINGER ROAD, BETHESDA MD 20817
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Diane L. Parks director 29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Mark E. Pearson director, 10 percent owner 3031 TISCH WAY, SUITE 505, SAN JOSE CA 95128
Preta Martina Cavazza other: Former 10% Owner VIA SUDAFRICA 20, ROME L6 00144
Enrico Cavazza other: Former 10% Owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Silvia Cavazza other: Former 10% Owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Francesca Cavazza other: Former 10% Owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Spa Essetifin 10 percent owner VIA SUDAFRICA 20, ROME L6 00144